This website is a presentation of myeloma and the NMSG. The content of the website is for information exclusively. The information given on this site is not meant to and cannot replace professional counseling or treatment by a doctor. The information is not to be used for diagnosing or determining a treatment.

NMSG does not guarantee for the correctness of information of this website or websites to which referrals are made. NMSG cannot be held responsible neither directly nor indirectly for any damage or loss caused by your or a third party´s use or misuse of the website. All rights to the website and to material on the website belong to NMSG. This also applies to all written entries sent to the website. Entries, which are sent to the website, become the property of NMSG and may without limitation be used by NMSG and are treated without confidence. Any dispute that may arise regarding this website or as a consequence of using this website is to be settled according to Danish Law. NMSG is not responsible for direct, random, consequently indirect or criminal damages which may occur due to the access to or the use of the content on this website, including computer viruses, regardless of the accurateness or completeness.

ABOUT NMSG

Nordic Myeloma Study Group (NMSG) was established in 1987 by Nordic hematologists with a special interest in clinical myeloma research.

NMSG is an independent Nordic organization of research, active MDs and Norwegian, Swedish, Icelandic, Finnish, Estonian, Lithuanian, and Danish clinics / hospitals who conduct clinical myeloma research. About 60 hematological clinics / hospitals - among these 25 university hospitals in these countries are a part of the NMSG.

 

The vision of NMSG is to ensure optimal evidence-based treatment of all myeloma patients in the Nordic countries through e.g. clinical and controlled studies with associated basic research on the disease and its biology.

 

NMSG holds biannual plenary meetings with a scientific, educational and organizational agenda. All NMSG members may participate in the plenary meetings. NMSG sponsors are invited to participate in the plenary meetings.

The NMSG has five Working Groups including:

· Clinical trial group – Headed by Fredrik Schjesvold

· Translational Research Group – Headed by Niels Abildgaard

· Real-World Data Group – Headed by Cecilie Hveding Blimark

· Flow Group – Headed by Mona Fenstad

· Cellular Therapy Group Headed by Hareth Nahi

· Pro and QoL Group – Headed by Lene Kongsgaard

The Executive Board consists of 15 members: 3 members from Norway, Sweden, Denmark and Finland and 1 member Iceland, Estonia and Lithuania.

Executive Board

The Executive Board consists of 15 members: 3 members from Norway, Sweden, Denmark and Finland and 1 member Iceland, Estonia and Lithuania.

Besides the board, Nmsg also has 27 NMSG coordinators who coordinating clinical researchers divided between the regional hospital regions with 6 regional coordinators in Norway, 9 in Sweden, 1 in Iceland, 6 in Denmark and 5 in Finland.

At present (2018), NMSG members are made up of 368 clinical researchers and MDs with an interest in myeloma.